Yes,

this is the slide that you were, and it's out of date already probably from, you know, when I put it together a number of weeks back.

But, yeah, this is exciting.

And just to notice here, this is pancreas cancer.

This is not lung cancer.

This is pancreas cancer in terms of where the field is moving.

Just to, again, to illustrate the potential here based on atargus and now drugs that have clear efficacy.

Anyhow, what about Deroxo plus GemNab?

Yes,

this is the slide that you were, and it's out of date already probably from, you know, when I put it together a number of weeks back.

But, yeah, this is exciting.

And just to notice here, this is pancreas cancer.

This is not lung cancer.

This is pancreas cancer in terms of where the field is moving.

Just to, again, to illustrate the potential here based on atargus and now drugs that have clear efficacy.

Anyhow, what about Deroxo plus GemNab?

What are they, and how common are they in pancreatic cancer?

Thank you so much.

Thanks for the opportunity to be here.

So the topic is RAS mutations in pancreas cancer, and it's a topic dear to all pancreatologists' heart.

So RAS mutations are present in almost every individual with this disease or alterations in the MAP kinase pathway, and basically, they're responsible for badness, right? They're responsible for growth, for metastasis, for angiogenesis, and that's been known forever in this disease.

Well, you know, many, many decades.

But what's fundamentally changed is that there's now an ability to effectively target this.

-with some of the side effects?